ISMP Links Invokana to Ketoacidosis
Filed in: Invokana
References
29, 2. J. (n.d.). SGLT2 inhibitors - a health gamble with a new class of drugs for diabetes.Overall Opioid Use Drops, but Oxycodone Use Grows Executive Summary. Retrieved from http://www.ismp.org/QuarterWatch/pdfs/2015Q4.pdf
FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. (2016, January 15). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm
FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2016, January 7). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm
FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). (2016, June 17). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm
FDA drug safety communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. (2016, May 18). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm500965.htm